Fig. 3: Cellular activation following vesatolimod administration. | npj Vaccines

Fig. 3: Cellular activation following vesatolimod administration.

From: Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

Fig. 3

A–D T and NK cell activation in both sham and vaccinated groups as measured by increase in cell surface CD69+ expression one day following vesatolimod administration at week 50 post-infection in CD4+ T cells (A), CD8+ T cells (B), CD56+ NK Cells (C), and CD16+ CD56- NK Cells (D). Statistical significance determined from two-way ANOVA with Bonferroni correction for multiple comparisons. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.

Back to article page